1 week Ago By Defense World Staff
American Century Companies Inc. acquired a new stake in shares of AtriCure, Inc. ( NASDAQ:ATRC – Free Report ) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC).
The fund acquired 16,872 shares of the medical device company’s stock, valued at approximately $516,000. Other hedge funds have also recently made changes to their positions in the company. State Street Corp raised its position in AtriCure by 4.
9% during the 3rd quarter. State Street Corp now owns 1,344,856 shares of the medical device company’s stock worth $37,710,000 after buying an additional 63,002 shares during the last quarter. Geode Capital Management LLC increased its stake in shares of AtriCure by 2.
9% in the third quarter. Geode Capital Management LLC now owns 1,152,628 shares of the medical device company’s stock worth $32,326,000 after acquiring an additional 32,676 shares during the period. Charles Schwab Investment Management Inc.
raised its holdings in shares of AtriCure by 1.2% during the fourth quarter. Charles Schwab Investment Management Inc.
now owns 399,428 shares of the medical device company’s stock worth $12,207,000 after purchasing an additional 4,844 shares during the last quarter. Bank of New York Mellon Corp lifted its position in AtriCure by 2.7% during the fourth quarter.
Bank of New York Mellon Corp now owns 258,272 shares of the medical device company’s stock valued at $7,893,000 after purchasing an additional 6,809 shares during the period. Finally, Raymond James Financial Inc. purchased a new stake in AtriCure in the fourth quarter valued at $3,716,000.
99.11% of the stock is owned by institutional investors and hedge funds. Wall Street Analysts Forecast Growth Several equities analysts have recently issued reports on ATRC shares.
Piper Sandler boosted their price objective on AtriCure from $40.00 to $50.00 and gave the company an “overweight” rating in a report on Thursday, February 13th.
Canaccord Genuity Group decreased their price target on AtriCure from $66.00 to $52.00 and set a “buy” rating for the company in a report on Friday, March 28th.
BTIG Research reaffirmed a “buy” rating on shares of AtriCure in a research note on Thursday, March 27th. Stifel Nicolaus boosted their target price on shares of AtriCure from $36.00 to $48.
00 and gave the company a “buy” rating in a research note on Thursday, February 13th. Finally, Oppenheimer increased their price target on shares of AtriCure from $36.00 to $45.
00 and gave the stock an “outperform” rating in a report on Thursday, February 13th. One equities research analyst has rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. According to MarketBeat.
com, the company has an average rating of “Moderate Buy” and a consensus target price of $49.44. AtriCure Price Performance Shares of NASDAQ ATRC opened at $32.
07 on Friday. The company has a debt-to-equity ratio of 0.13, a quick ratio of 2.
62 and a current ratio of 3.65. The firm has a fifty day moving average of $36.
01 and a 200 day moving average of $34.27. The firm has a market cap of $1.
57 billion, a PE ratio of -33.76 and a beta of 1.65.
AtriCure, Inc. has a one year low of $18.94 and a one year high of $43.
11. Insider Activity In related news, Director Karen Prange sold 6,100 shares of the business’s stock in a transaction that occurred on Wednesday, March 5th. The stock was sold at an average price of $38.
12, for a total transaction of $232,532.00. Following the completion of the sale, the director now directly owns 17,828 shares in the company, valued at approximately $679,603.
36. The trade was a 25.49 % decrease in their ownership of the stock.
The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website . Company insiders own 3.20% of the company’s stock.
AtriCure Profile ( Free Report ) AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation. Read More Five stocks we like better than AtriCure How to Use the MarketBeat Excel Dividend Calculator Robinhood Strategies Could Be a Game-Changer for Young Investors 3 Natural Gas Stocks That Offer Great Dividend Yields Are These 3 Retail Stocks Oversold or Really in Trouble? Russell 2000 Index, How Investors Use it For Profitable Trading IONQ & RGTI Join DARPA Quantum Initiative: High Stakes Are Ahead Want to see what other hedge funds are holding ATRC? Visit HoldingsChannel.
com to get the latest 13F filings and insider trades for AtriCure, Inc. ( NASDAQ:ATRC – Free Report ). Receive News & Ratings for AtriCure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AtriCure and related companies with MarketBeat.
com's FREE daily email newsletter ..
